ObjectiveTo discuss the implications of expanded genetic carrier screening for
preconception purposes based on our practice.MethodsOne hundred and forty-three potential gamete donors aged 20-32 years old
(µ=24, 127 females and 16 males), signed informed consent forms and
were selected according to the REDLARA guidelines. Blood or saliva samples
were examined by one of these genetic carrier screening methods: Genzyme
screening for Cystic Fibrosis (CF), Fragile X and Spinal Muscular Atrophy
(SMA); Counsyl Universal panel or Recombine Carrier Map.ResultsGenotyping results for all donors were analyzed; 41% (58/143) of donors were
identified as carriers for at least one condition. We found a carrier
frequency of 1/24 for CF, 1/72 for SMA and 0/120 for Fragile X syndrome.
Among the high-impact most prevalent conditions in our study (Carrier Map
group) were: 21-Hydroxilase-Deficient Congenital Nonclassical Adrenal
Hyperplasia (1/8), Factor V deficiency (1/12), Hemochromatosis: Type 1: HFE
Related (1/12), Short Chain Acyl-CoA (1/14) and MTHFR deficiency 1/3
(39%).ConclusionsThe rate of gamete donors identified as carriers of at least one condition
was 41%, which supports the offering of expanded carrier screening to our
population. Studies in Latin American populations could help customize
screening panels. The ART patient population has a unique opportunity to be
offered expanded carrier screening and appropriate counseling, to make its
best-informed decisions.